While UroGen Pharma Ltd has underperformed by -0.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, URGN fell by -29.65%, with highs and lows ranging from $20.70 to $8.94, whereas the simple moving average fell by -17.49% in the last 200 days.
On April 16, 2025, Scotiabank started tracking UroGen Pharma Ltd (NASDAQ: URGN) recommending Sector Outperform. Guggenheim also rated URGN shares as ‘Buy’, setting a target price of $40 on the company’s shares in an initiating report dated August 22, 2024. Jefferies February 08, 2023d the rating to Hold on February 08, 2023, and set its price target from $35 to $10. Berenberg initiated its ‘Buy’ rating for URGN, as published in its report on April 27, 2022. H.C. Wainwright’s report from April 16, 2020 suggests a price prediction of $57 for URGN shares, giving the stock a ‘Buy’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of UroGen Pharma Ltd (URGN)
Further, the quarter-over-quarter increase in sales is 4.40%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of UroGen Pharma Ltd’s future performance, with equity being one of the most critical indicators. Taking into account the quick ratio of the company, currently set at 5.81, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and URGN is recording an average volume of 418.77K. On a monthly basis, the volatility of the stock is set at 7.11%, whereas on a weekly basis, it is put at 5.85%, with a loss of -2.69% over the past seven days. Furthermore, long-term investors anticipate a median target price of $32.62, showing growth from the present price of $10.11, which can serve as yet another indication of whether URGN is worth investing in or should be passed over.
How Do You Analyze UroGen Pharma Ltd Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.09%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 80.50% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
URGN shares are owned by institutional investors to the tune of 80.50% at present.
